Know Your Formula, Know Your Food
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Sodium Selenate Hazard Summary Identification
Common Name: SODIUM SELENATE CAS Number: 13410-01-0 RTK Substance number: 1726 DOT Number: UN 2630 Date: November 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Sodium Selenate can affect you when breathed in and The following exposure limits are for Selenium compounds may be absorbed through the skin. (measured as Selenium): * Contact can irritate the skin and eyes. * Breathing Sodium Selenate can irritate the nose, throat OSHA: The legal airborne permissible exposure limit 3 and lungs causing coughing, wheezing and/or shortness of (PEL) is 0.2 mg/m averaged over an 8-hour breath. workshift. * High exposure can cause headache, nausea, vomiting, NIOSH: The recommended airborne exposure limit is coated tongue, metallic taste and garlic odor on the breath. 3 * Repeated exposure can cause pallor, nervousness and 0.2 mg/m averaged over a 10-hour workshift. mood changes. ACGIH: The recommended airborne exposure limit is * Sodium Selenate may damage the liver and kidneys and 3 affect the heart. 0.2 mg/m averaged over an 8-hour workshift. * The above exposure limits are for air levels only. When IDENTIFICATION skin contact also occurs, you may be overexposed, even Sodium Selenate is a white, sand-like solid. It is used as a though air levels are less than the limits listed above. medication and an insecticide. WAYS OF REDUCING EXPOSURE REASON FOR CITATION * Where possible, enclose operations and use local exhaust * Sodium Selenate is on the Hazardous Substance List ventilation at the site of chemical release. If local exhaust because it is regulated by OSHA and cited by ACGIH, ventilation or enclosure is not used, respirators should be DOT, NIOSH, DEP and EPA. -
Elemental and Semi-Elemental Formulas: Are They Superior to Polymeric Formulas?
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #34 Carol Rees Parrish, R.D., M.S., Series Editor Elemental and Semi-Elemental Formulas: Are They Superior to Polymeric Formulas? Diklar Makola Nutritional support, utilizing enteral nutrition formulas, is an integral part of the pri- mary and/or adjunctive management of gastrointestinal and other disorders with nutritional consequences. Four major types of enteral nutrition formulas exist includ- ing: elemental and semi-elemental, standard or polymeric, disease-specific and immune-enhancing. Although they are much more expensive, elemental and semi- elemental formulas are purported to be superior to polymeric or standard formulas in certain patient populations. The aim of this article is to evaluate whether this claim is supported by the literature and to ultimately show that except for a very few indica- tions, polymeric formulas are just as effective as elemental formulas in the majority of patients with gastrointestinal disorders. INTRODUCTION ease, facilitate “pancreatic rest” in pancreatitis and pre- he provision of nutritional support is an essential vent nutritional depletion that accompanies many GI part of the primary and adjunctive management of tract diseases. The factors leading to nutritional deple- T tion include: 1) impaired absorption of nutrients; many gastrointestinal (GI) disorders such as Crohn’s disease, cystic fibrosis, pancreatitis, head and 2) inadequate intake due to anorexia; 3) dietary restric- neck cancer, cerebrovascular accidents, etc. Nutritional tions; 4) increased intestinal losses; and 5) an increase in support can be used to induce remission in Crohn’s dis- nutritional demand that accompanies many catabolic states. Nutritional support can be provided by using Diklar Makola, M.D., M.P.H., Ph.D., Gastroenterology either total parenteral nutrition (PN) or total enteral Fellow, University of Virginia Health System, Digestive nutrition (EN), however EN when compared to PN has Health Center of Excellence, Charlottesville, VA. -
Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities. -
Electro-Activation of Potassium Acetate, Potassium Citrate and Calcium
Liato et al. SpringerPlus (2016) 5:1760 DOI 10.1186/s40064-016-3453-1 RESEARCH Open Access Electro‑activation of potassium acetate, potassium citrate and calcium lactate: impact on solution acidity, Redox potential, vibrational properties of Raman spectra and antibacterial activity on E. coli O157:H7 at ambient temperature Viacheslav Liato1,2, Steve Labrie1,3 and Mohammed Aïder1,2,4* *Correspondence: [email protected] Abstract 1 Institute of Nutrition and Functional Foods (INAF), Aims: To study the electro-activation of potassium acetate, potassium citrate and Université Laval, Quebec, QC calcium lactate aqueous solutions and to evaluate their antimicrobial effect against E. G1V 0A6, Canada coli O157:H7 at ambient temperature. Full list of author information is available at the end of the Methods and results: Potassium acetate, potassium citrate and calcium lactate aque- article ous solutions were electrically excited in the anodic compartment of a four sectional electro-activation reactor. Different properties of the electro-activated solutions were measured such as: solutions acidity (pH and titratable), Redox potential and vibrational properties by Raman spectroscopy. Moreover, the antimicrobial activity of these solu- tions was evaluated against E. coli O157:H7. The results showed a pH decrease from 7.07 0.08, 7.53 0.12 and 6.18 0.1 down to 2.82 0.1, 2.13 0.09 and 2.26 0.15, after ±180 min of electro-activation± ± of potassium acetate,± potassium± citrate and calcium± lactate solution, respectively. These solutions were characterized by high oxidative ORP of 1076 12, 958 11 and 820 14 mV, respectively. -
Reflections on Dentifrice Ingredients, Benefits and Recommendations a Peer-Reviewed Publication Written by Fiona M
Earn 4 CE credits This course was written for dentists, dental hygienists, and assistants. Reflections on Dentifrice Ingredients, Benefits and Recommendations A Peer-Reviewed Publication Written by Fiona M. Collins, BDS, MBA, MA This course has been made possible through an unrestricted educational grant from Colgate-Palmolive, Co. The cost of this CE course is $59.00 for 4 CE credits. Cancellation/Refund Policy: Any participant who is not 100% satisfied with this course can request a full refund by contacting PennWell in writing. Educational Objectives dentifrice use. Recommendations should be based on an The overall goal of this article is to provide dental profession- individual patient’s specific needs and desires as well as the als with information on the active and inactive ingredients in scientific support for a dentifrice. Both the Food and Drug dentifrices and their benefits. Administration (FDA) and the American Dental Associa- Upon completion of this course, the clinician will be able tion (ADA) have played roles in controlling (FDA) and ac- to do the following: cepting (ADA) dentifrices. 1. List active ingredients in dentifrices and their therapeutic benefits. Dentifrice Ingredients 2. List inactive ingredients in dentifrices and their functions. Dentifrices contain both active and inactive ingredients. Ac- 3. Know the roles of the FDA and ADA with respect to tive ingredients are those that offer a therapeutic benefit, while over-the-counter dentifrices. inactive ingredients are non-therapeutic and also contribute 4. Understand the considerations involved and importance of to the physicochemical properties of the dentifrice – its feel, recommending OTC dentifrices for individual patients. -
A Hypoallergenic Infant Formula Comprising Extensively Hydrolyzed
Central Journal of Human Nutrition & Food Science Bringing Excellence in Open Access Research Article *Corresponding author Esther Matencio, Department of Research and Development, Hero Spain S.A., Avda. Murcia 1, 30820 Alcantarilla, Murcia, Spain, Tel: 34-968-898- A Hypoallergenic Infant Formula 900; Fax: 34-968-800-727; Email: Submitted: 27 June 2016 Comprising Extensively Hydrolyzed Accepted: 20 July 2016 Published: 22 July 2016 Protein for the Nutritional ISSN: 2333-6706 Copyright Treatment of Infants with Cow’s © 2016 Matencio et al. OPEN ACCESS Milk Allergy: Safety, Tolerance and Keywords • Cow’s milk protein allergy • Extensively hydrolyzed infant formula • Immunity Efficacy • Infant formula Esther Matencio1*, José Maldonado2,7, Josune Olza3-5, M Dolores Mesa3,5,7, • Long chain polyunsaturated fatty acids Fernando Romero1, Gaspar Ros6, Pedro Abellán1 and Ángel Gil3-5 1Research and Development Department, Hero Spain S.A., Avda. Murcia 1, 30820, Alcantarilla, Murcia, Spain 2Hospital Virgen de las Nieves, Avda. de las Fuerzas Armadas, 2, 18014 Granada, Spain 3Institute of Nutrition and Food Technology “José Mataix”, Department of Biochemistry, and Molecular Biology II, University of Granada, Biomedical Research Center, Avenida del Conocimiento s/n, 18100 Armilla, Granada, Spain 4CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Madrid, Spain 5Instituto de Investigación Biosanitaria ibs.GRANADA, Spain 6Department of Food Science and Nutrition, Faculty of Veterinary Sciences, University of Murcia, Campus de Espinardo, 30071 Espinardo, Murcia, Spain 7Retics funded by the PN I+D+I 2008-2011 (SPAIN), ISCIII- Sub-directoratee General for Research Assessment and Promotion and the European Regional Development Fund (ERDF), Ref. RD 12/0026 Abstract Background: There is strong evidence about the role of extensively hydrolyzed formula (eHF) in the treatment of cow’s milk protein allergy (CMPA). -
(12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji Et Al
US00721 1656B2 (12) United States Patent (10) Patent No.: US 7,211,656 B2 Mukerji et al. (45) Date of Patent: May 1, 2007 (54) DESATURASE GENES, ENZYMES ENCODED Doerks et al., TIG 14(6): 248-250, Jun. 1998.* THEREBY, AND USES THEREOF Smith et al. Nature Biotechnology 15: 1222-1223, Nov. 15, 1997.* Brenner, S.E., TIG 15(4): 132-133, Apr. 1999.* (75) Inventors: Pradip Mukerji, Gahanna, OH (US); Bork et al., TIG 12(10): 425-427, Oct. 1996.* Suzette L. Pereira, Westerville, OH Leslie, C. G. et al., “Dietary (n-9) Eicosatrienoic Acid from a (US); Yung-Sheng Huang, Upper Cultured Fungus Inhibits Leukotriene B4 Synthesis in Rats and the Arlington, OH (US) Effect Is Modified by Dietary Linoleic Acid' ', Amer Journ of Clin Nutrit, 126(6): 1534-1540 (1996). Jareonkitmongkol, S., et al., “Production of an Eicosapentaenoic (73) Assignee: Abbott Laboratories, Abbott Park, IL Acid-Containing Oil by a A12 Desaturase-Defective Mutant of (US) Mortierella alpina 1S-4”, Journ of the Amer Oil Chemists Soc. 70(2): 119-123 (1993). (*) Notice: Subject to any disclaimer, the term of this Pereira, S.L., et al., “A novel (p-fatty acid desaturase involved in the patent is extended or adjusted under 35 biosynthesis of eicosapentaenoic acid”. The Biohem Journ, U.S.C. 154(b) by 444 days. 378(2):665-671 (2004). Ziboh, V.A., et al., Metabolism of polyunsaturated fatty acids by (21) Appl. No.: 10/060,793 skin epidermal enzymes: generation of anti-inflammatory and antiproliferative metabolites 1-3, Amer Journ of Clin Nutri, (22) Filed: Jan. -
Felix Ekness
ABSTRACT A Synthetic Biology Approach to Engineering Bacterial Two- Component Systems for Sensor Development and Discovery of Anti-Virulence Agents by Felix Ekness Bacterial two-component systems (TCSs) are the largest family of signal transduction pathways that enable bacteria to sense a diversity of stimuli including small peptides, environmental pollutants, and light. Canonical TCSs are composed of a transmembrane sensor histidine kinase (SK) that converts stimulus detection into phosphorylation of a cognate response regulator (RR). Upon phosphorylation, the cytoplasmic RR binds target output promoters, hereby modulating gene expression. TCSs are valuable sensors for synthetic biology due to their diverse sensing capabilities and straightforward transduction of detected stimulus into transcriptional regulation. TCSs are also emerging targets for novel therapeutic development due to their extensive role in regulating bacterial virulence and antibiotic resistance. Although TCSs are exciting sensors for synthetic biology and targets for therapeutic applications, most TCSs remain difficult to harness for applications and study due to output promoters that are unknown, subject to cross- regulation, or silent in heterologous hosts. In the first portion of my work, I develop a method to overcome the hurdles in characterizing and utilizing TCSs as biosensors. Through the framework of synthetic biology, I demonstrate that the two largest families of RR DNA binding domains (DBDs) can be interchanged with remarkable flexibility, enabling the corresponding TCSs to be rewired to synthetic output promoters. In collaboration with Kristina Daeffler, we exploit this plasticity to eliminate cross-regulation and in collaboration with Brian Landry, we un-silence a gram-negative TCS in a gram-positive host and engineer a sensor with over 1,300-fold activation. -
Properties of Peanut (KAC431) Protein Hydrolysates and Their Impact on the Quality of Gluten-Free Rice Bread
foods Article Properties of Peanut (KAC431) Protein Hydrolysates and Their Impact on the Quality of Gluten-Free Rice Bread Suphat Phongthai 1,2,*, Nuttapon Singsaeng 1, Rossarin Nhoo-ied 1, Thipubol Suwannatrai 1, Regine Schönlechner 3, Kridsada Unban 1, Warinporn Klunklin 1 , Thunnop Laokuldilok 1,2, Yuthana Phimolsiripol 1,2 and Saroat Rawdkuen 4 1 School of Agro-Industry, Faculty of Agro-Industry, Chiang Mai University, Chiang Mai 50100, Thailand; [email protected] (N.S.); [email protected] (R.N.-i.); [email protected] (T.S.); [email protected] (K.U.); [email protected] (W.K.); [email protected] (T.L.); [email protected] (Y.P.) 2 Cluster of High Value Product from Thai Rice for Health, Chiang Mai University, Chiang Mai 50100, Thailand 3 Institute of Food Technology, Department of Food Science and Technology, BOKU-University of Natural Resources and Life Sciences, 18, 1190 Vienna, Austria; [email protected] 4 Unit of Innovative Food Packaging and Biomaterials, School of Agro-Industry, Mae Fah Luang University, Chiang Rai 57100, Thailand; [email protected] * Correspondence: [email protected] Received: 18 June 2020; Accepted: 15 July 2020; Published: 16 July 2020 Abstract: Protein hydrolysates (PH) with a degree of hydrolysis (DH) of 5%, 10%, and 13% from two varieties of peanut were prepared using two commercial enzymes, Alcalase and Flavourzyme. The content of essential amino acids (30,290 mg/100 g) and hydrophobic amino acids (34,067 mg/100 g) of the peanut variety Kalasin 2 (KAC431) protein was higher than that of a common variety, Kalasin 1 (KAC1) (p < 0.05). -
Innovative Prolonged-Release Oral Alkalising Formulation
www.nature.com/scientificreports OPEN Innovative prolonged‑release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults C. Guittet1, C. Roussel‑Maupetit1, M. A. Manso‑Silván 1, F. Guillaumin1, F. Vandenhende2 & L. A. Granier 1* A multi-particulate fxed-dose combination product, consisting of a combination of two alkalising salts formulated as prolonged-release granules, ADV7103, was developed to obtain a sustained and prolonged alkalising efect. The specifc release of both types of granules was shown in vitro through their dissolution profles, which indicated that potassium citrate was released within the frst 2–3 h and potassium bicarbonate up to 10–12 h after administration. The long-lasting coverage of ADV7103 was confrmed through a randomised, placebo-controlled, double-blind, two-period study, measuring its efect on urine pH in healthy adults (n = 16) at doses of alkalising agent ranging between 0.98 and 2.88 meq/kg/day. A signifcant increase of urine pH with a positive dose–response in healthy adult subjects was shown. Urine pH above 7 was maintained during 24 h with a dosing equivalent to 1.44 meq/kg twice a day, while urine pH was below 6 most of the time with placebo. The efect observed was non-saturating within the range of doses evaluated and the formulation presented a good safety profle. ADV7103 provided an efective prolonged release of alkalising salts to cover a 12-h efect with adequate tolerability and could aford a twice a day (morning and evening) dosing in patients requiring long-term treatment. -
Safety Assessment of Bovine Milk Proteins and Protein Derivatives As Used in Cosmetics
Safety Assessment of Bovine Milk Proteins and Protein Derivatives as Used in Cosmetics Status: Tentative Report for Public Comment Release Date: April 28, 2017 Panel Meeting Date: September 11-12, 2017 All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2017 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, DPA. This safety assessment was prepared by Christina L. Burnett, Scientific Analyst/Writer and Bart Heldreth, Ph.D., Chemist CIR. © Cosmetic Ingredient Review 1620 L St NW, Suite 1200◊ Washington, DC 20036-4702 ◊ ph 202.331.0651 ◊fax 202.331.0088 ◊ [email protected] ABTRACT The Cosmetic Ingredient Review (CIR) Expert Panel (the Panel) reviewed the safety of 16 bovine milk proteins and protein-derived ingredients, which function mainly as skin and hair conditioning agents in personal care products. -
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](https://docslib.b-cdn.net/cover/8870/ehealth-dsi-ehdsi-v2-2-2-or-ehealth-dsi-master-value-set-1028870.webp)
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01